All Drugs and Chemicals

Amino Acids

Tyrosine Kinase Inhibitors

Tyrosine

SGX523 Capsules

Michael Gordon, MD

Ramesh Ramanathan, MD

SGX523 is a drug which acts by blocking the function of an enzyme called MET. MET activity may be important in growth and survival of some types of cancer. This Phase I trial is studying the safety, side effects, and best dose of SGX523 when given to patients with advanced cancer, and how well it inhibits MET activity in tumors.

Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, Ona Twice Daily, Interrupted Schedule in Patients With Advanced Cancer

SGX Pharmaceuticals, Inc.

Terry Rugg, MD

Lee Rosen, MD

Howard Burris, MD

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	NCT00607399	Advanced Cancer	SGX523 Capsules	18 Years -	SGX Pharmaceuticals, Inc.
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	NCT00606879	Advanced Cancer	SGX523 Capsules	18 Years -	SGX Pharmaceuticals, Inc.
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors	NCT00607399	Advanced Cancer	SGX523 Capsules	18 Years -	SGX Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for receptor tyrosine kinase inhibitor (rtki)